Developing the World‐Wide FINGERS biorepository for dementia risk reduction trials
Alzheimer's & Dementia · 2026-11 · 22 (11)
DOI: 10.1002/alz.71949 ↗Abstract
Abstract INTRODUCTION Dementia prevention research increasingly uses multimodal interventions. Harmonized biomarker practices are essential to enable comparable cross‐population analysis with initiatives such as the World‐Wide FINGERS (WW‐FINGERS) network contributing to this effort. METHODS To advance globally representative biomarker research in dementia prevention trials, we conducted a cross‐sectional, network‐wide survey of WW‐FINGERS teams assessing biospecimen collection, processing and storage, biomarker measurements, and readiness for harmonized procedures. RESULTS Most studies (30/39) had or were developing biorepositories; four planned collection and five had none. Practices were broadly aligned, but remaining variability highlights priority targets for harmonization. Clinical biomarkers (lipids, glucose, liver/kidney function) were obtained even in lower‐resourced settings. Many studies measured Alzheimer's disease and related dementias (ADRD) biomarkers (blood‐based amyloid/tau and neurodegeneration; cerebrospinal fluid where feasible) and increasingly used multi‐omics platforms. Evidence‐based preanalytical guidance were provided. CONCLUSION The WW‐FINGERS biorepository provides a world‐first platform for harmonized biomarker discovery across diverse populations in dementia prevention, helping to reduce inequities in research participation, accelerating globally representative strategies.
EUVIMED